Loading stock data…
CARL
$9.48+0.59 (+6.64%)
Market ClosedLast close May 1
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.48
Potential Upside
5%
Whystock Fair Value$9.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. I...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$269.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.97%
Volume
Today's trading volume
102,126
Recent News
Carlsmed Showcases Personalized Spine Fusion Gains, Cervical Expansion and Medicare Tailwinds at Needham Conf
Carlsmed (NASDAQ:CARL) used its presentation at Needham’s 25th Annual Healthcare Conference to highlight progress in its patient-specific digital surgery platform, recent clinical outcomes data, and evolving reimbursement landscape as it expands from lumbar into cervical spine fusion. Personalized
Carlsmed Unveils Personalized Spine Platform, Targets $70M-$75.5M 2025 Revenue at Conference
Carlsmed (NASDAQ:CARL) used its presentation at Canaccord Genuity’s Musculoskeletal Conference to outline its mission to improve outcomes and reduce the cost of spine surgery by lowering reoperation rates in spine fusion procedures through a personalized, data-driven technology platform. CEO Mike Co
Carlsmed Q4 Earnings Call Highlights
Carlsmed (NASDAQ:CARL) reported rapid growth in the fourth quarter and full year 2025, highlighting record revenue, gross margin expansion, and increasing surgeon adoption as the company scaled its personalized spine surgery platform following its July initial public offering. 2025 highlights: reve
Carlsmed Inc (CARL) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...
Carlsmed Inc (CARL) reports impressive revenue growth and operational efficiency, but faces ongoing financial hurdles as it navigates market expansion.
Bullish Carlsmed Insiders Loaded Up On US$8.10m Of Stock
In the last year, multiple insiders have substantially increased their holdings of Carlsmed, Inc. ( NASDAQ:CARL...